The REST trial, registered as NCT07294950, will randomise people living with obesity and without preexisting cardiovascular disease all currently receiving semaglutide for weight management, all having achieved at least 10% prior weight reduction with no further loss over the past 12 weeks to either a gradual dose reduction over 16 weeks or immediate discontinuation [6]
Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus
I cannot emphasize enough- if youre on a GLP-1 RA, you need to be vigilant to eat adequate protein, to resistance train regularly, and to get good sleep
glutathione tablets with hyaluronic acid, alpha lipoic acid, NAC, and grape seed extract.
drug prices by up to 80% , reflecting the reality that Americans pay up to four times more than patients in OECD countries